PPARG — The Insulin Sensitivity Gene
PPARG| Full name: Peroxisome Proliferator-Activated Receptor Gamma is a nuclear receptor| Nuclear receptors are proteins that bind to DNA and directly regulate gene expression in response to hormones and metabolites
that regulates fatty acid storage and glucose metabolism. It's the target of
thiazolidinedione| Thiazolidinediones (e.g. pioglitazone) are diabetes drugs that work by activating PPARG to improve insulin sensitivity drugs used to treat type 2 diabetes.
The Mechanism
The Pro12Ala variant (rs1801282) is a missense mutation in exon B of PPARG,
where a cytosine-to-guanine change substitutes proline with alanine at position
12 (p.Pro12Ala). This occurs in the ligand-independent activation domain of the
PPARγ2 isoform. The Ala (G) allele reduces PPARG transcriptional activity
slightly, which paradoxically improves insulin sensitivity — likely because
excessive PPARG activity promotes fat storage.
The Evidence
The original discovery by Deeb et al. | Deeb et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet, 1998 demonstrated
that the Ala allele reduces receptor activity and is associated with lower BMI
and better insulin sensitivity in Finnish populations.
Altshuler et al. | Altshuler et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet, 2000 confirmed in over 3,000 individuals
that the common Pro allele (C) carries a modest 1.25-fold increase in diabetes
risk compared to the Ala allele (G).
A HuGE meta-analysis of 60 studies | Gouda et al. The association between the PPARG2 Pro12Ala gene variant and T2DM. Am J Epidemiol, 2010 involving 32,849 cases
and 47,456 controls confirmed the protective effect of Ala12 (OR 0.86).
Practical Implications
The Pro (C) allele is the common variant (~75% of Europeans are CC).
Having one or two copies of the Ala (G) allele is protective — it improves
how your cells respond to insulin. The G allele is rare in African populations
(~1%) but more common in European and South Asian populations (~11-12%).
Interactions
PPARG interacts with TCF7L2 (rs7903146) in determining overall diabetes risk.
If you carry the protective Ala allele here but the risk T allele at TCF7L2,
the effects may partially offset each other. PPARG is also the target of
thiazolidinedione drugs — carriers of Ala12 may respond differently to these
medications.
All genotypes
Common Pro/Pro variant
You have the most common PPARG genotype (Pro/Pro), shared by about 75% of people of European descent. Your insulin sensitivity is typical for the population. The Pro allele has slightly higher PPARG activity, which is associated with a modest 1.25-fold increase in type 2 diabetes risk compared to Ala carriers — but this is a small effect that is easily managed through lifestyle.
Two Ala alleles - best insulin sensitivity
You have two copies of the protective Ala allele (Ala/Ala), a genotype found in only about 2% of Europeans. This is associated with the best insulin sensitivity of all PPARG genotypes and the lowest PPARG-related diabetes risk.
One Ala allele - improved insulin sensitivity
You carry one copy of the protective Ala allele (Pro/Ala), shared by about 23% of Europeans. This variant is associated with better insulin sensitivity compared to the common Pro/Pro genotype, conferring about a 14% reduced risk of type 2 diabetes.